Tag Archives: ASCO
Primary Peritoneal Mesothelioma: How Aggressive Should We Be?
SOURCE: ASCO, 2004 Annual Meeting D. M. Labow, D. G. Coit, D. Kelsen, J. Shia, S. Freeman, M. R. Weiser; Memorial Sloan-Kettering Cancer Center, New York, NY Background: Primary peritoneal mesothelioma is a rare disease with an unpredictable clinical course. This has led to a variety of treatment options, ranging from minimal debulking, debulking with [...]
Single Dose Electron Beam Radiation Therapy for Tumor Wound Seeding Prophylaxis in Mesothelioma.
SOURCE: ASCO, 2004 Annual Meeting T. C. Lo, J. Cassady, J. F. Beamis; Lahey Clinic Medical Center, Burlington, MA Background: Wound seeding by tumor cells in the course of malignant disease is a well-documented phenomenon. Mesothelioma is one of the malignancies notoriously known to manifest symptomatic tumor seeding along tissue tracks from thoracoscopy, chest tube [...]
Earlier Findings Showed That Alimta+Cisplatin Helped These Same Patients Live Longer
SOURCE: Eli Lilly and Company Thoracic Expert: Patients With Asbestos-Related Cancer Report Better Quality of Life With Alimta+Cisplatin CHICAGO–(BUSINESS WIRE)–June 2, 2003– Patients enduring an agonizing form of cancer often associated with asbestos exposure reported that the combination of Alimta ® (pemetrexed) and cisplatin enabled them to enjoy a better overall quality of life, compared [...]
Phase III Program ofONCONASE for The Treatment of Patients with Unresectable Malignant Mesothelioma
SOURCE: Alfacell Corporation BLOOMFIELD, N.J., April 3 /PRNewswire-FirstCall/ — Alfacell Corporation today announced that the encouraging survival data from its Phase II multicenter trial of ONCONASE®, led the Company to conduct a Phase III program which included the evaluation of ONCONASE as a single agent at 33 centers across the United States and the combination [...]
